Non Alcoholic Steatohepatitis (NASH) Market
Non Alcoholic Steatohepatitis (NASH) Market - Global Industry Assessment & Forecast
Segments Covered
- By Drug Type Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc, Others
- By Sales Channel Hospital Pharmacy, Online Provider, Retail Pharmacy
- By Region North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Snapshot
Base Year: | 2022 |
Forecast Years: | 2023 - 2030 |
Historical Years: | 2017 - 2021 |
Revenue 2022: | USD 2511.97 Million |
Revenue 2030: | USD 108428.91 Million |
Revenue CAGR (2023 - 2030): | 60.10% |
Fastest Growing Region (2023 - 2030) | Asia Pacific |
Largest Region (2022): | North America |
Customization Offered
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Research Methodology: Non Alcoholic Steatohepatitis (NASH) Market by Drug Type by Sales Channel by Region - Global Market Assessment, 2021 - 2028
Secondary Research
Primary Research:
The later stage covers data validation and collection from primary research. The information gained/procured from the secondary data sources is validated through extensive primary interviews with industry experts across the Non Alcoholic Steatohepatitis (NASH) supply chain. The primary research is also conducted to identify key players in the market and to gather and validate already procured information pertaining to their market-specific financial information. Moreover, primary research is used to gain/validate information about:
- Non Alcoholic Steatohepatitis (NASH) market size at regional and country level
- Key industry players and their market share and Non Alcoholic Steatohepatitis (NASH) market-specific sales/revenue
- Understanding of the Non Alcoholic Steatohepatitis (NASH) supply chain and overall ecosystem
Data Triangulation and Market Size Estimations
After arriving at the global market numbers, top-down and bottom-up approaches are used to estimate, validate and finalize the market size of the Non Alcoholic Steatohepatitis (NASH) market. After the determination of the overall market size, the market is divided into various segments and sub-segments. Moreover, these same approaches mentioned above were used to derive and estimate market numbers for mentioned segments/sub-segments in the market. During the data triangulation process, the data was analyzed by employing various data models and statistical techniques to arrive at exact statistics and market size for each segment/sub-segment of the market. The data is analyzed and triangulated by considering all the key market impacting factors from both supply and demand side of Non Alcoholic Steatohepatitis (NASH) market.
FAQ
Frequently Asked Question
What is the global demand for Non Alcoholic Steatohepatitis (NASH) in terms of revenue?
-
The global Non Alcoholic Steatohepatitis (NASH) valued at USD 2511.97 Million in 2022 and is expected to reach USD 108428.91 Million in 2030 growing at a CAGR of 60.10%.
Which are the prominent players in the market?
-
The prominent players in the market are Genfit, Allergan plc (Tobira Therapeutics, Inc.), Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galectin Therapeutics, Inc..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 60.10% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Non Alcoholic Steatohepatitis (NASH) include
- High Prevalence of Hypertension
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Non Alcoholic Steatohepatitis (NASH) in 2022.